Welcome to our dedicated page for Newmont SEC filings (Ticker: NEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 300-page Newmont annual report isn鈥檛 just time consuming鈥攊t means untangling geology tables, reclamation liabilities, and hedge positions buried deep in footnotes. If you have ever searched for Newmont insider trading Form 4 transactions or tried to pinpoint how labor disruptions affect production in a Newmont 8-K material events explained, you already know the challenge.
Stock Titan removes that friction. Our AI reviews every Newmont quarterly earnings report 10-Q filing, flags changes in all-in sustaining cost, and distills reserve revisions into plain language. Want alerts on a director鈥檚 gold-price-timed sale? AG真人官方-time notifications on Newmont Form 4 insider transactions real-time appear the moment EDGAR posts. From a Newmont annual report 10-K simplified to a concise Newmont proxy statement executive compensation breakdown, we turn dense disclosures into clear, decision-ready insights.
Here鈥檚 what you can do:
- Compare segment cash costs using our Newmont earnings report filing analysis.
- Track environmental remediation obligations without wading through accounting notes.
- Spot Newmont executive stock transactions Form 4 before market chatter starts.
- Save hours by understanding Newmont SEC documents with AI instead of manual reviews.
Every 10-K, 10-Q, 8-K, S-4, or Form 4 is captured the instant it reaches EDGAR, then summarized by our expert-trained models so you never miss a material detail. Newmont SEC filings explained simply鈥攁ll in one place, updated in real time.
BioSig Technologies (BSGM) has called a virtual special meeting to seek shareholder approval for several highly dilutive and governance-altering actions tied to its recently closed acquisition of Streamex Exchange Corp.
- Proposal 1: Ratify issuance of 鈮�109.1 million common shares (plus one Super Voting Preferred share) to Streamex sellers. If approved, Streamex holders would ultimately control 75% of BioSig鈥檚 fully-diluted equity; existing investors fall to 25%.
- Proposal 2: Authorize stock underlying convertible debentures to YA II PN, Ltd.
- Proposal 3: Add 10,359,211 shares to the 2023 LTIP (total 14,735,806).
- Proposal 4: Permit issuance of 鈮�19.99% of outstanding shares under a Standby Equity Purchase Agreement (SEPA) with Yorkville.
- Proposal 5: Increase authorized common shares from 200 million to 500 million.
- Proposal 6: Stagger the board into three classes.
The board unanimously recommends voting 鈥淔OR鈥� all proposals. Quorum is one-third of voting power; most items need simple majority of votes cast, but the classified board requires majority of all outstanding shares. Risk disclosure highlights extensive dilution, regulatory uncertainty around Streamex鈥檚 gold-tokenization model, and integration challenges. Record date and meeting date remain blank pending SEC clearance.
Bloom Energy Corp. (BE) 鈥� Form 144 filing: Insider Daniel Berenbaum has notified the SEC of his intent to sell 8,000 common shares through Morgan Stanley Smith Barney on 24 Jul 2025. The proposed sale is valued at $262,850, implying an indicative price of roughly $32.86 per share.
The filing also discloses that Berenbaum has already disposed of 48,300 shares over the last three months in eight separate transactions, generating aggregate gross proceeds of approximately $1.02 million. Recent sales include 6,000 shares on 9 Jul 2025 ($168k) and 14,889 shares on 21 May 2025 ($276.9k). No relationship to the issuer is specified in the form, and the signer affirms possession of no undisclosed material adverse information.
While Form 144 only signals an intention to sell and not a completed transaction, investors often view continued insider liquidation鈥攅specially following significant recent sales鈥攁s a potential negative sentiment indicator.
Global Interactive Technologies, Inc. (Nasdaq: GITS) filed an amended Form 8-K (8-K/A) to expand and clarify its June 25, 2025 current report. The amendment adds Item 3.02 disclosure regarding an earlier private placement and provides additional detail on regulatory compliance.
- Private placement: Between April 20 and July 31, 2023 the company (then Hanryu Holdings) issued 462,847 common shares to 124 Korean investors at KRW 1,279 (鈮� US$10.00) per share, raising KRW 5.92 billion (鈮� US$4.63 million).
- Securities Act exemption: The shares were sold offshore to non-U.S. persons under Section 4(a)(2) and Regulation S; no U.S. directed selling efforts occurred.
- Regulatory context: The filing notes the company has appealed sanctions imposed by Korea鈥檚 Securities and Futures Commission related to the placement; the appeal is pending.
- Reason for amendment: (i) include the unregistered-sales item, (ii) state the exemption basis, and (iii) update the KRW-to-USD conversion. All other information from the original 8-K remains unchanged.
The capital raise represents modest dilution and a small cash infusion. The key investor takeaway is the clarification of legal exemptions while an SFC enforcement action remains unresolved.
On July 1, 2025, SeaStar Medical Holding Corporation (ICU) Chief Medical Officer Kevin Chung filed a Form 4 disclosing the vesting and conversion of 5,000 restricted stock units (RSUs) into common shares. The transaction was coded 鈥淢,鈥� signifying a conversion of derivative equity awards rather than an open-market purchase, and carried a price of $0 per share.
After the transaction, Dr. Chung now directly owns 48,184 ICU shares. This figure incorporates 25,000 shares that were previously reported as unvested RSUs in Table II and have been moved to Table I. The filing also corrects a prior one-share rounding error, and no derivative RSUs remain reportable from this grant.
The RSUs originated from a November 15, 2024 grant of 15,000 units that vest in three equal annual tranches beginning July 1, 2024; the current filing reflects the first installment. Because the shares were received under a pre-arranged compensation plan at no cost, the event does not inject new capital into the company nor constitute an open-market confidence signal. Nevertheless, it modestly increases insider equity alignment and provides transparency regarding executive compensation.
Amendment No. 5 to Schedule 13D discloses that the Silver Lake鈥揳ffiliated reporting persons (Global Blue Holding L.P., SL Globetrotter L.P., SL Globetrotter GP Ltd., Silver Lake Technology Associates III Cayman L.P. and Silver Lake (Offshore) AIV GP III Ltd.) have tendered all of their equity interests in Global Blue Group Holding AG (鈥淕B鈥�) in connection with the cash tender offer launched by Shift4 Payments, Inc. and its Swiss merger subsidiary.
The offer, which commenced on 21 March 2025 and expired one minute after 11:59 p.m. (NYC time) on 2 July 2025, met all conditions. The Silver Lake vehicles tendered:
- 34,871,499 ordinary shares held by Cayman Holdings at $7.50 per share
- 4,939,137 Series A preferred shares (convertible into ordinary shares) at $10.00 per share
- 91,230,811 ordinary shares held by Globetrotter at $7.50 per share
- 11,970,487 Series A preferred shares held by Globetrotter at $10.00 per share
In addition, 2,701,935 Global Blue warrants (Cayman Holdings) and 6,548,415 warrants (Globetrotter) were cashed-out and are no longer exercisable. As a result of these transactions, the reporting persons now report 0 shares beneficially owned (0.0% of the class) and thereby cease to be 5% holders as of 3 July 2025.
Following completion of the offer, director Joseph Osnoss resigned from the Global Blue board. The filing attaches an amended Annex A listing directors of the Silver Lake general partners and adds Exhibit 99.1 containing that information.
This amendment is limited to updating ownership, identity disclosures and purpose-of-transaction details; all other information in prior filings remains unchanged.
Form 4 Overview 鈥� Appian Corporation (APPN)
Director Albert G.W. Biddle III reported a routine equity award on 1 July 2025. The filing shows:
- 1,046 Class A shares acquired at $0 pursuant to Appian鈥檚 2017 Equity Incentive Plan and the Non-Employee Director Compensation Policy.
- Post-transaction ownership rises to 31,478 directly held shares.
- Mr. Biddle also controls several family trusts and a corporate entity, bringing his total indirect holdings to 128,937 shares (15,479 shares in each of three trusts and 82,500 shares through Jack Biddle Inc.).
No sales or derivative transactions were disclosed, and no options or warrants were exercised. The grant represents a ~0.65 % increase in Mr. Biddle鈥檚 aggregate beneficial ownership (now approximately 160,415 shares).
This appears to be a standard, non-market purchase for board compensation rather than a signal of strategic intent or a change in insider sentiment. The transaction is not likely to have a material impact on Appian鈥檚 share float or valuation.
Newmont Corporation (NEM) 鈥� Form 144 filing: Insider Peter I. Toth has notified the SEC of his intent to sell 3,000 common shares on or about 01 Jul 2025 through Fidelity Brokerage Services on the NYSE. The proposed sale has an estimated market value of $176,250, versus the company鈥檚 outstanding share count of 1,112,996,934; the transaction therefore represents roughly 0.0003 % of shares outstanding.
The shares were acquired via restricted-stock vesting on 27 Jul 2024 and are being sold for the account of Mr. Toth. He attests that he possesses no undisclosed material adverse information. Under Rule 144, the filer also discloses a recent selling pattern: in the past three months Mr. Toth sold 9,000 shares (3,000 each on 01 Apr, 01 May, and 02 Jun 2025) for total gross proceeds of $462,090.
The filing signals continued insider disposals but the absolute volume is immaterial relative to Newmont鈥檚 float. Nevertheless, investors often monitor repetitive insider sales for sentiment cues. No financial performance metrics, earnings data, or corporate strategic information are included in this notice.